Seaport Global Reports Initiation of Nektar Therapeutics (NKTR) with $120.0000 Target; Parametric Portfolio Associates Raised Its Rayonier Advanced Materials (RYAM) Holding

Rayonier Advanced Materials Inc. (NYSE:RYAM) Logo

In a a report issued to clients and investors on 20 April, analysts at Seaport Global has initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR). The firm set a Buy rating with $120.0000, giving 39.19% to target.

Parametric Portfolio Associates Llc increased Rayonier Advanced Materials (RYAM) stake by 17.5% reported in 2017Q4 SEC filing. Parametric Portfolio Associates Llc acquired 36,305 shares as Rayonier Advanced Materials (RYAM)’s stock rose 5.81%. The Parametric Portfolio Associates Llc holds 243,724 shares with $4.98 million value, up from 207,419 last quarter. Rayonier Advanced Materials now has $1.14 billion valuation. The stock increased 0.64% or $0.14 during the last trading session, reaching $22.07. About 1.31 million shares traded or 38.89% up from the average. Rayonier Advanced Materials Inc. (NYSE:RYAM) has risen 69.18% since April 22, 2017 and is uptrending. It has outperformed by 57.63% the S&P500.

Parametric Portfolio Associates Llc decreased Schneider Elect Sa (SBGSY) stake by 43,878 shares to 2.55 million valued at $43.26 million in 2017Q4. It also reduced Bt Group Plc Adr (NYSE:BT) stake by 120,746 shares and now owns 510,729 shares. Avon Products Inc (NYSE:AVP) was reduced too.

Among 6 analysts covering Rayonier Advanced Materials Inc (NYSE:RYAM), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Rayonier Advanced Materials Inc had 24 analyst reports since August 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $18.0 target in Sunday, August 20 report. The company was downgraded on Friday, August 21 by Citigroup. The stock has “Buy” rating by Vertical Research on Friday, May 26. RBC Capital Markets maintained Rayonier Advanced Materials Inc. (NYSE:RYAM) on Wednesday, February 3 with “Sector Perform” rating. The firm has “Buy” rating by Vertical Research given on Monday, May 29. RBC Capital Markets downgraded Rayonier Advanced Materials Inc. (NYSE:RYAM) on Friday, October 30 to “Sector Perform” rating. RBC Capital Markets maintained the shares of RYAM in report on Wednesday, July 19 with “Buy” rating. The stock of Rayonier Advanced Materials Inc. (NYSE:RYAM) has “Underperform” rating given on Friday, December 4 by RBC Capital Markets. The stock of Rayonier Advanced Materials Inc. (NYSE:RYAM) has “Buy” rating given on Tuesday, May 30 by RBC Capital Markets. The stock of Rayonier Advanced Materials Inc. (NYSE:RYAM) has “Buy” rating given on Thursday, January 11 by RBC Capital Markets.

Since December 13, 2017, it had 0 insider purchases, and 18 sales for $68.39 million activity. ROBIN HOWARD W had sold 83,333 shares worth $4.64M on Wednesday, December 13. 160,000 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $14.89 million were sold by Doberstein Stephen K. Hora Maninder sold 29,498 shares worth $3.03 million. 4,879 shares were sold by Nicholson John, worth $404,664. $3.05 million worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Lingnau Lutz on Thursday, April 5. Thomsen Jillian B. also sold $1.41 million worth of Nektar Therapeutics (NASDAQ:NKTR) shares. The insider KUEBLER CHRISTOPHER A sold $3.90M.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 EPS, down 2.38% or $0.01 from last year’s $-0.42 per share. After $-0.14 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14% negative EPS growth.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $78.10’s average target is -9.41% below currents $86.21 stock price. Nektar Therapeutics had 27 analyst reports since August 6, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Wednesday, October 18 report. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 8. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, January 10 report. As per Wednesday, August 30, the company rating was maintained by Roth Capital. Canaccord Genuity initiated it with “Buy” rating and $35.0 target in Thursday, November 9 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Monday, November 13. The rating was maintained by Roth Capital on Tuesday, May 30 with “Buy”. The rating was maintained by Mizuho on Thursday, March 29 with “Buy”. On Monday, April 9 the stock rating was maintained by Cowen & Co with “Buy”. On Thursday, July 20 the stock rating was maintained by Roth Capital with “Buy”.

The stock decreased 4.37% or $3.94 during the last trading session, reaching $86.21. About 2.72 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 22, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It worsened, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Clarivest Asset Mngmt Ltd Limited Liability Company holds 0.05% in Nektar Therapeutics (NASDAQ:NKTR) or 48,259 shares. Prelude Cap Mngmt Lc holds 0% or 97 shares. Barclays Public Limited Liability holds 389,812 shares. Voloridge Invest Mngmt Limited Liability Corporation holds 0.2% or 154,564 shares. Putnam Investments Lc owns 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 85,265 shares. Columbus Circle accumulated 242,114 shares or 0.27% of the stock. 189,100 were accumulated by Amundi Pioneer Asset Mgmt. Zeke Advsr owns 7,142 shares. Alliancebernstein Lp owns 263,506 shares. Jefferies Grp Ltd Company owns 20,000 shares or 0.01% of their US portfolio. Artal Gp accumulated 0.36% or 400,000 shares. Tocqueville Asset Mngmt Ltd Partnership stated it has 0.21% in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Vanguard Gru Incorporated has 0.04% invested in Nektar Therapeutics (NASDAQ:NKTR). First Light Asset Limited Liability, Minnesota-based fund reported 351,741 shares. Aqr Llc owns 173,239 shares.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart